Michael D. Parkins
Elite in Pseudomonas Stutzeri Infections

Michael D. Parkins

Calgary, AB, CA 
Elite in Pseudomonas Stutzeri Infections
Calgary, AB, CA 
OverviewLocationsClinical Research

Overview

Michael Parkins practices in Calgary, Canada. Mr. Parkins is rated as an Elite expert by MediFind in the treatment of Pseudomonas Stutzeri Infections. His top areas of expertise are Cystic Fibrosis, Pseudomonas Stutzeri Infections, Pulmonary Aspergilloma, Vulvectomy, and Lung Transplant.

His clinical research consists of co-authoring 115 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 24 articles in the study of Pseudomonas Stutzeri Infections.

Gender
Male

Locations

Calgary, AB, Canada
Other Locations
Canada
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Controlled Trial of Prednisone in Cystic Fibrosis Pulmonary Exacerbations
Randomized Controlled Trial of Prednisone in Cystic Fibrosis Pulmonary Exacerbations
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drug: Prednisone
Study Phase: Phase 3
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drug: ELX-02 Ribosomal-Selective Glycoside
Study Phase: Phase 2
A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
A Phase 1b Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drug: CB-280 Arginase Inhibitor
Study Phase: Phase 1
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis
Enrollment Status: Completed
Publish Date: September 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Enrollment Status: Completed
Publish Date: February 06, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

115 Total Publications

Metagenomic analysis after selective culture enrichment of hospital and community wastewater enhances antimicrobial resistance gene detection.
Metagenomic analysis after selective culture enrichment of hospital and community wastewater enhances antimicrobial resistance gene detection.
Journal: mBio
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Parkins's expertise for a condition
ConditionClose
View All 22 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile